Table 1.
Demographics and Clinical Characteristics of COVID-19 Patients
| Characteristic | Total (n = 44) | Severe/Critical (n = 8) | Non-Severe (n = 36) | p value |
|---|---|---|---|---|
| Age, years | 54(3–77) | 62.5(54–77) | 44(3–71) | 0.008* |
| Gender Male | 21(47.7) | 5(62.5) | 16(44.4) | 0.35 |
| Female | 23(52.3) | 3(37.5) | 20(45.6) | |
| Signs and symptoms | ||||
| Fever | 29(65.9) | 7(87.5) | 22(61.1) | 0.15 |
| Cough | 18(40.9) | 3(37.5) | 15(41.7) | 0.83 |
| Fatigue | 5(11.4) | 3(37.5) | 2(5.5) | 0.01* |
| Nasal discharge | 2(4.5) | 0(0) | 2(5.5) | 0.49 |
| Pain (headache/sore throat/muscle aches, etc) | 9(20.4) | 2(25) | 7(19.4) | 0.72 |
| T, °C | 37.0(36.5–37.8) | 37.7(37.3–38.0) | 36.8(36.5–37.7) | 0.04* |
| Underlying diseases(N/Y) | 16(36.4) | 5(62.5) | 11(30.5) | 0.09 |
| Circulatory diseases (hypertension, coronary heart disease) | 7(15.9) | 2(25) | 5(13.9) | 0.44 |
| Respiratory basic diseases (chronic bronchitis, lung cancer) | 3(6.8) | 2(25) | 1(2.8) | 0.02* |
| Endocrine system basic diseases (diabetes) | 3(6.8) | 2(25) | 1(2.8) | 0.02* |
| Other systemic diseases (fractures, cerebral infarction, etc.) | 5(11.4) | 1(12.5) | 4(11.1) | 0.91 |
| Laboratory findings | ||||
| White blood cell count, ×109/L | 4.61(3.67–6.48) | 3.52(3.14–4.59) | 4.82(3.83–6.56) | 0.04* |
| Lymphocyte count, ×109/L | 1.60 (1.08–2.13) | 0.85(0.45–1.46) | 1.76(1.36–2.46) | 0.001* |
| Neutrophil count, ×109/L | 2.30(1.79–3.47) | 2.08(1.30–3.34) | 2.36(1.88–3.61) | 0.38 |
| Monocyte count, ×109/L | 0.47(0.37–0.66) | 0.34(0.26–0.52) | 0.49(0.40–0.71) | 0.06 |
| NLR | 1.78(0.4–9.38) | 2.16(0.74–9.38) | 1.70 (0.40–5.68) | 0.025* |
| PCT | 2(4.5) | 1(12.8) | 1(2.8) | 0.23 |
| CRP, mg/L | 2.45(0.56–7.62) | 22.0(8.68–42.5) | 1.15(0.48–5.06) | 0.001* |
| CD3(+) T lymphocytes,/ul | 1057(742.8–1561) | 565 (226.0–794.5) | 1162(891.3–1734) | 0.001* |
| CD3(+)CD4(+) T lymphocytes,/ul | 579(408.3–831.5) | 325(174.5–483.8) | 631.5(449.8–842.5) | 0.006* |
| CD3(+)CD8(+) T lymphocytes,/ul | 355(263.8–514.5) | 159(64.5–281.8) | 457.5(318.8–553.0) | 0.0002* |
| PaO2, mmHg | 99.9(86.6–105.0) | 91.1(75.7–101.2) | 101.0(89.1–105.3) | 0.12 |
| CT imaging features | ||||
| One or both lungs | 2(0–2) | 2(1–2) | 1(0–2) | 0.02* |
| Number of lung lobes (0–5) | 2next (0–5) | 5(1–5) | 1(0–5) | 0.001* |
| Ground glass lesions | 29(65.9%) | 7(87.5%) | 22(61.1%) | 0.15 |
| Consolidation | 7(15.9%) | 3(37.5%) | 4(11.1%) | 0.06 |
| Bronchial abnormalities | 4(9.1%) | 2(25%) | 2(5.5%) | 0.08 |
| Mediastinal lymph node enlargement | 1(2.3%) | 1(12.5%) | 0(0) | 0.04* |
| Pleural effusion | 1(2.3%) | 1(12.5%) | 0(0) | 0.04* |
Note: *P<0.05.
Abbreviations: T, temperature; NLR, neutrophil-to-lymphocyte ratio; PCT, procalcitonin; CRP, C-reactive protein; PaO2, arterial partial pressure of oxygen.